Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Last trade$5.71
Day change-$0.09 (-1.55%)
Day range$5.60 – $5.93
Volume50,972
Market cap$15M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.12M
Price / earnings
—
Price / book
1.2×
Price / sales
3.22×
EV / sales
0.48×
EV / EBITDA
-0.08×
Profitability
Earnings per share
-$11.02
Return on assets
-71.23%
Return on equity
-227.37%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.61×
Quick ratio
2.61×
Cash ratio
1.63×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.54M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BOLT, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$5K
$26K
$2.5M
$2.17M
$1.8M
$1.22M
$0
$1.14M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$5K
$26K
$2.5M
$2.17M
$1.8M
$1.22M
$0
$1.14M
Selling, general and administrative
$2.42M
$2.8M
$3.12M
$3.34M
$3.52M
$3.83M
$3.95M
$3.8M
Research and development
$5.15M
$4.83M
$4.99M
$6.54M
$7.5M
$9.51M
$11.72M
$13.79M
Total operating expenses
$8.38M
$7.63M
$9.59M
$9.87M
$11.01M
$13.34M
$16.92M
$17.58M
Operating income
-$8.37M
-$7.6M
-$7.09M
-$7.7M
-$9.21M
-$12.12M
-$16.92M
-$16.44M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$7.72M
-$7.24M
-$6.63M
-$7.14M
-$8.56M
-$11.04M
-$15.94M
-$15.18M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.72M
-$7.24M
-$6.63M
-$7.14M
-$8.56M
-$11.04M
-$15.94M
-$15.18M
Net income attributable to common shareholders
-$7.72M
-$7.24M
-$6.63M
-$7.14M
-$8.56M
-$11.04M
-$15.94M
-$15.18M
EBITDA
-$7.4M
-$7.4M
-$5.35M
-$7.41M
-$8.86M
-$11.72M
-$15.24M
-$16M
Basic earnings per share
-$4.57
-$4.31
-$3.84
-$3.72
-$4.46
-$5.76
-$8.32
-$7.93
Diluted earnings per share
-$4.57
-$4.31
-$3.84
-$3.72
-$4.46
-$5.76
-$8.32
-$7.93
Recent news
Company coverage with links to the original publishers.
Coherus Oncology reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.22, with revenues of $14.27 million falling 10.25% short of expectations. The stock has declined 45.8% year-to-date, significantly underperforming the S&P 500's 7.8% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Caribou Biosciences reported a Q3 loss of $0.25 per share, beating consensus estimates of $0.27 loss, with a 7.41% earnings surprise. Revenue came in at $1.61 million, surpassing estimates by 7.13%, though down from $2.2 million year-ago. The stock has declined 72.1% year-to-date and carries a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.
Adaptive Biotechnologies reported Q3 2026 earnings of $0.02 per share, beating consensus estimates of a $0.10 loss, with a 120% earnings surprise. Revenues of $83.9 million exceeded estimates by 16.81%, though down from $93.97 million year-over-year. The stock has gained 58.9% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Bolt Biotherapeutics announced positive results from a Phase 1 study of its cancer immunotherapy BDC-3042, which showed favorable safety, biological activity, and signs of anti-tumor activity. The company is seeking a partner to advance the development of BDC-3042.
Bolt Biotherapeutics presented positive preclinical data for its next-generation cancer immunotherapy candidate BDC-4182 and key learnings from its Phase 1 trial of BDC-1001, suggesting that enhanced immune activation could lead to greater efficacy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.